Pliant Therapeutics, Inc.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On July 9, 2026 (the “Effective Date”), the Board of Directors (the “Board”) of Pliant Therapeutics, Inc. (the “Company”) increased the authorized size of the Board from seven to nine members, and, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), appointed each of Robert Iannone, M.D., M.S.C.E. as a Class I director, and Flavia Borellini, Ph. D. as a Class II director, to fill the newly-created vacancies. The Board also appointed Dr. Iannone to serve as a member of the Research and Development Committee of the Board (the “R&D Committee”) and Dr. Borellini to serve as chairperson of the R&D Committee upon the recommendation of the Nominating and Governance Committee. There are no arrangements or understandings between Dr. Iannone or Dr. Borellini and any other person pursuant to which either one of them was appointed as a director of the Company. The Board has determined that both Dr. Iannone and Dr. Borellini qualify as independent directors and are qualified to serve under the applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) and the listing rules of The Nasdaq Stock Market LLC. There has been no transaction, nor is there any currently proposed transaction, involving either Dr. Iannone or Dr. Borellini that would require disclosure under Item 404(a) of Regulation S-K. As of the Effective Date, Dr. Iannone and Borellini will participate in the Company’s non-employee director compensation arrangements, which are generally described under the heading “Director Compensation” in the Company’s Definitive Proxy Statement for the 2026 Annual Meeting of Stockholders as filed with the SEC on April 22, 2026. Under these arrangements, each of Drs. Iannone and Borellini will receive an annual retainer of $40,000 starting on the Effective Date, with payment pro-rated for any partial period of service. In addition, Dr. Iannone will receive an annual retainer of $7,500 for his service as a member of the R&D Committee, with payment pro-rated for any partial period of service, and Dr. Borellini will receive an annual retainer of $15,000 for her service as chairperson of the R&D Committee, with payment pro-rated for any partial period of service. On the Effective Date, each of Drs. Iannone and Borellini also received an option to purchase 60,000 shares of the Company’s common stock, which will vest in substantially equal monthly installments over three years, subject to his or her continuous service as a member of the Board. The Company also entered into its standard form of indemnification agreement with each of Drs. Iannone and Borellini.